## Celanese (NYSE: CE) — filings-based deep dive (10-K / 10-Q / proxy) ### 0) Quick “map” (so you can jump around) 1) **Business + segment model** (what they sell, how they make money) 2) **Financial core** (3-year P&L + cash flow) 3) **Segment economics** (Engineered Materials vs. Acetyl Chain) 4) **Balance sheet & capital structure** (debt stack, refinancing, deleveraging) 5) **Key “watch items”** (impairments, restructuring, macro + end-market sensitivity) 6) **Governance & incentives** (proxy: board refreshment, comp framing) --- ## 1) What Celanese is (as described in filings): two-segment chemicals + engineered polymers company Celanese reports **two principal business segments: Engineered Materials and Acetyl Chain**. ["two business segments"](0001306830-25-000027|0) They describe operations as global, with **56 global production facilities plus 20 strategic affiliate production facilities**, and **12,163 employees** as of Dec 31, 2024. ["56 global production facilities"](0001306830-25-000027|0) ["employed 12,163"](0001306830-25-000027|0) ### Segment “economic logic” (the key difference) - **Engineered Materials**: positioned as **solutions / value-in-use pricing** and “generally independent” of raw material cost movements (meaning margin can expand/contract with raw materials). ["value-in-use"](0001306830-25-000083|0) - **Acetyl Chain**: pricing is **more directionally tied to industry utilization and raw material costs** and tends to **lag** raw material moves. ["directional correlation"](0001306830-25-000083|0) That split matters: in downcycles, Engineered Materials can be hit by volume and mix, while Acetyl Chain can be hit by both **spread compression** and **industry oversupply** dynamics (Celanese explicitly describes “greater supply than demand” in Acetyl Chain in 2024/2025 narratives). ["greater supply than demand"](0001306830-25-000083|0) ["greater supply than demand"](0001306830-25-000225|0) --- ## 2) Financial core: 3-year P&L (GAAP) + margins (computed) ### Table A — Consolidated income statement snapshot (USD millions) | Metric | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Net sales | 10,280 ["Net sales 10,280"](0001306830-25-000027|0) | 10,940 ["Net sales 10,940"](0001306830-25-000027|0) | 9,673 ["Net sales 9,673"](0001306830-25-000027|0) | | Gross profit | 2,356 ["Gross profit 2,356"](0001306830-25-000027|0) | 2,603 ["Gross profit 2,603"](0001306830-25-000027|0) | 2,380 ["Gross profit 2,380"](0001306830-25-000027|0) | | **Gross margin** | **22.9% (computed)** | **23.8% (computed)** | **24.6% (computed)** | | Operating profit (loss) | (697) ["Operating profit (loss) (697)"](0001306830-25-000027|0) | 1,687 ["Operating profit (loss) 1,687"](0001306830-25-000027|0) | 1,378 ["Operating profit (loss) 1,378"](0001306830-25-000027|0) | | **Operating margin** | **-6.8% (computed)** | **15.4% (computed)** | **14.2% (computed)** | | Net earnings (loss) available to Celanese | (1,522) ["Net earnings (loss) available"](0001306830-25-000027|0) | 1,960 ["Net earnings (loss) available"](0001306830-25-000027|0) | 1,894 ["Net earnings (loss) available"](0001306830-25-000027|0) | | **Net margin** | **-14.8% (computed)** | **17.9% (computed)** | **19.6% (computed)** | **How to read FY2024:** the “headline” GAAP loss year is driven by **Other (charges) gains, net = $(1,744) million**. ["Other (charges) gains, net"](0001306830-25-000027|0) --- ## 3) Cash generation (and why it weakened in FY2024) ### Table B — Cash flow bridge (USD millions) | Metric | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Net cash provided by operating activities | 966 ["Net cash provided"](0001306830-25-000027|0) | 1,899 ["Net cash provided"](0001306830-25-000027|0) | 1,819 ["Net cash provided"](0001306830-25-000027|0) | | Capital expenditures (PP&E) | (435) ["Capital expenditures"](0001306830-25-000027|0) | (568) ["Capital expenditures"](0001306830-25-000027|0) | (543) ["Capital expenditures"](0001306830-25-000027|0) | | **“OCF – capex”** | **531 (computed)** | **1,331 (computed)** | **1,276 (computed)** | | Interest paid (net of capitalized) | 701 ["Interest paid"](0001306830-25-000027|0) | 780 ["Interest paid"](0001306830-25-000027|0) | 122 ["Interest paid"](0001306830-25-000027|0) | | Taxes paid (net of refunds) | 349 ["Taxes paid"](0001306830-25-000027|0) | 237 ["Taxes paid"](0001306830-25-000027|0) | 273 ["Taxes paid"](0001306830-25-000027|0) | Management explains the FY2024 OCF decline (vs. FY2023) primarily via **unfavorable trade working capital**, **lower earnings excluding non-cash impairment effects**, and **higher cash taxes**. ["unfavorable trade working capital"](0001306830-25-000027|0) ["decrease in Net earnings"](0001306830-25-000027|0) ["increase in cash taxes paid"](0001306830-25-000027|0) --- ## 4) Segment economics: where the money is made (and lost) ### Table C — Segment P&L (reportable segments + “Other Activities”) (USD millions) | Year | Segment | Net sales | Operating profit (loss) | Notable driver inside segment view | |---|---|---:|---:|---| | FY2024 | Engineered Materials | 5,607 ["Net sales 5,607"](0001306830-25-000027|0) | (1,179) ["Operating profit (loss) (1,179)"](0001306830-25-000027|0) | Other charges (incl. impairment) concentrated here ["Other (charges) gains, net"](0001306830-25-000027|0) | | FY2024 | Acetyl Chain | 4,763 ["Net sales 4,763"](0001306830-25-000027|0) | 951 ["Operating profit (loss) 951"](0001306830-25-000027|0) | More resilient operating profit than EM in FY2024 ["Operating profit (loss) 951"](0001306830-25-000027|0) | | FY2024 | Other Activities | — ["—"](0001306830-25-000027|0) | (469) ["(469)"](0001306830-25-000027|0) | Corporate/other costs live here ["Other Activities"](0001306830-25-000027|0) | | FY2023 | Engineered Materials | 6,149 ["Net sales 6,149"](0001306830-25-000027|0) | 1,083 ["Operating profit (loss) 1,083"](0001306830-25-000027|0) | FY2023 includes JV gain & much lower charges ["Gain (loss) on disposition"](0001306830-25-000027|0) | | FY2023 | Acetyl Chain | 4,884 ["Net sales 4,884"](0001306830-25-000027|0) | 1,109 ["Operating profit (loss) 1,109"](0001306830-25-000027|0) | — | | FY2022 | Engineered Materials | 4,024 ["Net sales 4,024"](0001306830-25-000027|0) | 429 ["Operating profit (loss) 429"](0001306830-25-000027|0) | — | | FY2022 | Acetyl Chain | 5,743 ["Net sales 5,743"](0001306830-25-000027|0) | 1,447 ["Operating profit (loss) 1,447"](0001306830-25-000027|0) | — | **Interpretation (what this implies structurally):** - Celanese’s consolidated volatility in FY2024 is **not** “broad-based margin collapse” alone—it is **heavily driven by Engineered Materials** swinging from profit to a large operating loss, while Acetyl Chain remained solidly profitable. ["Operating profit (loss)"](0001306830-25-000027|0) --- ## 5) Balance sheet & leverage: the central strategic constraint ### 5.1 Balance sheet snapshot (FY2024 year-end, GAAP) From the FY2024 10-K consolidated balance sheet: - **Total assets:** $22,857 million. ["Total assets 22,857"](0001306830-25-000027|0) - **Goodwill:** $5,387 million; **Intangibles, net:** $3,641 million. ["Goodwill 5,387"](0001306830-25-000027|0) ["Intangible assets, net 3,641"](0001306830-25-000027|0) - **Long-term debt (net):** $11,078 million; **Total debt:** $12,579 million; **Cash:** $962 million. ["Long-term debt"](0001306830-25-000027|0) ["Total debt"](0001306830-25-000027|0) ["Cash and cash equivalents 962"](0001306830-25-000027|0) ### 5.2 Debt stack (FY2024 year-end): “many notes + term loan + revolver” The 10-K gives a detailed long-term debt schedule (USD millions). Here’s the “shape” of it: - Senior notes across multiple maturities (2025 through 2033), plus a **term loan due 2027 ($880m)**, plus bonds/loans/finance leases. ["Senior unsecured term loan due 2027"](0001306830-25-000027|0) - The 10-K notes that an **S&P downgrade to BB+** increased coupon rates (step-ups) for certain notes. ["downgraded… to BB+"](0001306830-25-000027|0) ### Table D — Selected long-term debt lines at Dec 31, 2024 (USD millions) | Instrument (selected) | Balance | |---|---:| | Senior unsecured term loan due 2027 | 880 ["term loan due 2027"](0001306830-25-000027|0) | | Senior unsecured notes due 2027, 6.165% | 2,000 ["notes due 2027"](0001306830-25-000027|0) | | Senior unsecured notes due 2032, 6.379% | 1,000 ["notes due 2032"](0001306830-25-000027|0) | | Senior unsecured notes due 2033, 6.700% (step-up noted) | 1,000 ["notes due 2033"](0001306830-25-000027|0) ["increasing the interest rates"](0001306830-25-000027|0) | | Total long-term debt (gross subtotal) | 12,527 ["Subtotal 12,527"](0001306830-25-000027|0) | | Less: current installments | (1,393) ["Current installments"](0001306830-25-000027|0) | | Long-term debt (net) | 11,078 ["Total 11,078"](0001306830-25-000027|0) | ### 5.3 “Deleveraging mode” becomes explicit in 2025 disclosures In the Q3 2025 10-Q, management explicitly discusses leverage and steps taken: - They state the M&M Acquisition increased leverage and they **paused share repurchases**, and **reduced the quarterly dividend by ~95% beginning in Q1 2025** (as part of deleveraging). ["paused our share repurchase program"](0001306830-25-000225|0) ["reduce our quarterly dividend by approximately 95 percent"](0001306830-25-000225|0) - They also describe refinancing/tender activity and a new revolving credit agreement. ["new revolving credit agreement"](0001306830-25-000225|0) --- ## 6) “Watch items” that dominate the debate: impairments + restructuring + cyclicality ### 6.1 Impairments (repeat theme across 2024–2025) - FY2024: Celanese shows **impairment losses impacting goodwill** (Engineered Materials) in the goodwill rollforward. ["Impairment losses (1,517)"](0001306830-25-000027|0) - Q3 2025: Celanese reports a **non-cash goodwill impairment loss of $1.1 billion** and **trade name impairments (including Zytel®)**; it also notes an annual indefinite-lived intangible impairment loss of **$346 million** (primarily Zytel®). ["impairment loss on goodwill of $1.1 billion"](0001306830-25-000225|0) ["impairment loss of $346 million"](0001306830-25-000225|0) **Why this matters:** when goodwill/intangibles are a large fraction of assets (FY2024: goodwill $5.387B + intangibles $3.641B), the equity story becomes sensitive to (i) discount rates and (ii) end-market assumptions used in impairment testing. ["Goodwill 5,387"](0001306830-25-000027|0) ["Intangible assets, net 3,641"](0001306830-25-000027|0) ### 6.2 Restructuring and footprint actions FY2024 includes plant closure actions (e.g., Uentrop Germany polymerization units and Mechelen Belgium facility) with exit/shutdown costs disclosed in Note 4. ["intended closure"](0001306830-25-000027|0) ["Total 90"](0001306830-25-000027|0) ### 6.3 Cyclicality & end-market demand In Q3 2025 MD&A, Celanese attributes Net sales declines to **lower volumes (weaker global economic conditions)** and **pricing pressure** (especially Acetyl Chain supply/demand imbalance). ["weaker global economic conditions"](0001306830-25-000225|0) ["greater supply than demand"](0001306830-25-000225|0) --- ## 7) Governance & incentives (proxy disclosures) ### 7.1 Board refreshment + leadership structure The 2025 proxy describes board refreshment since 2022 and a transition to an **independent Chair** structure in 2025 (and dissolution of the Lead Independent Director role as of Dec 31, 2024). ["moving from… Lead Independent Director… to an Independent Chair"](0001306830-25-000083|0) ["role of Lead Independent Director was dissolved"](0001306830-25-000083|0) ### 7.2 How the proxy frames performance (useful “management lens”) The proxy’s performance highlight section states FY2024: - **Net sales $10,280m**, **GAAP diluted loss per share of $13.86**, and **Adjusted EPS of $8.37** (non-GAAP). ["2024 net sales of $10,280"](0001306830-25-000083|0) ["GAAP diluted loss per share of $13.86"](0001306830-25-000083|0) ["Adjusted EPS(1) of $8.37"](0001306830-25-000083|0) *(Those non-GAAP measures are in the proxy with reconciliations referenced to Exhibit A, but the detailed recon is not included in the excerpt we pulled.)* ["See “Exhibit A”"](0001306830-25-000083|0) ### 7.3 Director compensation structure (baseline economics of governance) The proxy spells out the base director comp components and committee chair fees. ["Annual cash retainer"](0001306830-25-000083|0) ["Annual time-based restricted stock units"](0001306830-25-000083|0) --- ## 8) A practical “investor checklist” (built from the disclosures above) ### A) Earnings quality / normalization - Separate **core operating performance** from **Other (charges) gains** (FY2024 included $(1.744)B). ["Other (charges) gains, net"](0001306830-25-000027|0) - Track whether impairment risk continues (Q3 2025 shows additional large impairments). ["Asset impairments"](0001306830-25-000225|0) ### B) Deleveraging trajectory - Monitor **total debt vs. cash** and debt maturity/refinancing actions. ["Total debt"](0001306830-25-000027|0) ["Cash and cash equivalents"](0001306830-25-000027|0) - Watch capital allocation: they explicitly **paused repurchases** and **cut dividends ~95%** starting Q1 2025. ["paused our share repurchase program"](0001306830-25-000225|0) ["reduce our quarterly dividend by approximately 95 percent"](0001306830-25-000225|0) ### C) Segment inflection signals - Engineered Materials: volume/pricing + any incremental “other charges.” ["Operating profit (loss)"](0001306830-25-000027|0) - Acetyl Chain: spread environment (supply > demand) + lag effects. ["greater supply than demand"](0001306830-25-000225|0) ### D) ESG / climate disclosure risk (not “ESG marketing”—financial/regulatory angle) Celanese explicitly flags climate-related **regulatory, physical, and transition risks** in its risk-factor discussion and notes ongoing GHG measurement/reporting efforts. ["financial, regulatory, physical and transition risks"](0001306830-25-000027|0) ["Scope 1 and Scope 2"](0001306830-25-000027|0) --- If you want to “use this interactively” without any back-and-forth: treat Sections **2–6** as modules. The fastest way to go deeper is to anchor on **(i) Engineered Materials impairment + recovery**, **(ii) Acetyl Chain cycle**, or **(iii) refinancing/deleveraging path**, because those are the main drivers repeatedly emphasized across the 10-K and 10-Q. ["Other (charges) gains, net"](0001306830-25-000027|0) ["greater supply than demand"](0001306830-25-000225|0) ["deleveraging efforts"](0001306830-25-000225|0)

## Celanese (NYSE: CE) — filings-based deep dive (10-K / 10-Q / proxy) ### 0) Quick “map” (so you can jump around) 1) **Business + segment model** (what they sell, how they make money) 2) **Financial core** (3-year P&L + cash flow) 3) **Segment economics** (Engineered Materials vs. Acetyl Chain) 4) **Balance sheet & capital structure** (debt stack, refinancing, deleveraging) 5) **Key “watch items”** (impairments, restructuring, macro + end-market sensitivity) 6) **Governance & incentives** (proxy: board refreshment, comp framing) --- ## 1) What Celanese is (as described in filings): two-segment chemicals + engineered polymers company Celanese reports **two principal business segments: Engineered Materials and Acetyl Chain**. ["two business segments"](0001306830-25-000027|0) They describe operations as global, with **56 global production facilities plus 20 strategic affiliate production facilities**, and **12,163 employees** as of Dec 31, 2024. ["56 global production facilities"](0001306830-25-000027|0) ["employed 12,163"](0001306830-25-000027|0) ### Segment “economic logic” (the key difference) - **Engineered Materials**: positioned as **solutions / value-in-use pricing** and “generally independent” of raw material cost movements (meaning margin can expand/contract with raw materials). ["value-in-use"](0001306830-25-000083|0) - **Acetyl Chain**: pricing is **more directionally tied to industry utilization and raw material costs** and tends to **lag** raw material moves. ["directional correlation"](0001306830-25-000083|0) That split matters: in downcycles, Engineered Materials can be hit by volume and mix, while Acetyl Chain can be hit by both **spread compression** and **industry oversupply** dynamics (Celanese explicitly describes “greater supply than demand” in Acetyl Chain in 2024/2025 narratives). ["greater supply than demand"](0001306830-25-000083|0) ["greater supply than demand"](0001306830-25-000225|0) --- ## 2) Financial core: 3-year P&L (GAAP) + margins (computed) ### Table A — Consolidated income statement snapshot (USD millions) | Metric | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Net sales | 10,280 ["Net sales 10,280"](0001306830-25-000027|0) | 10,940 ["Net sales 10,940"](0001306830-25-000027|0) | 9,673 ["Net sales 9,673"](0001306830-25-000027|0) | | Gross profit | 2,356 ["Gross profit 2,356"](0001306830-25-000027|0) | 2,603 ["Gross profit 2,603"](0001306830-25-000027|0) | 2,380 ["Gross profit 2,380"](0001306830-25-000027|0) | | **Gross margin** | **22.9% (computed)** | **23.8% (computed)** | **24.6% (computed)** | | Operating profit (loss) | (697) ["Operating profit (loss) (697)"](0001306830-25-000027|0) | 1,687 ["Operating profit (loss) 1,687"](0001306830-25-000027|0) | 1,378 ["Operating profit (loss) 1,378"](0001306830-25-000027|0) | | **Operating margin** | **-6.8% (computed)** | **15.4% (computed)** | **14.2% (computed)** | | Net earnings (loss) available to Celanese | (1,522) ["Net earnings (loss) available"](0001306830-25-000027|0) | 1,960 ["Net earnings (loss) available"](0001306830-25-000027|0) | 1,894 ["Net earnings (loss) available"](0001306830-25-000027|0) | | **Net margin** | **-14.8% (computed)** | **17.9% (computed)** | **19.6% (computed)** | **How to read FY2024:** the “headline” GAAP loss year is driven by **Other (charges) gains, net = $(1,744) million**. ["Other (charges) gains, net"](0001306830-25-000027|0) --- ## 3) Cash generation (and why it weakened in FY2024) ### Table B — Cash flow bridge (USD millions) | Metric | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Net cash provided by operating activities | 966 ["Net cash provided"](0001306830-25-000027|0) | 1,899 ["Net cash provided"](0001306830-25-000027|0) | 1,819 ["Net cash provided"](0001306830-25-000027|0) | | Capital expenditures (PP&E) | (435) ["Capital expenditures"](0001306830-25-000027|0) | (568) ["Capital expenditures"](0001306830-25-000027|0) | (543) ["Capital expenditures"](0001306830-25-000027|0) | | **“OCF – capex”** | **531 (computed)** | **1,331 (computed)** | **1,276 (computed)** | | Interest paid (net of capitalized) | 701 ["Interest paid"](0001306830-25-000027|0) | 780 ["Interest paid"](0001306830-25-000027|0) | 122 ["Interest paid"](0001306830-25-000027|0) | | Taxes paid (net of refunds) | 349 ["Taxes paid"](0001306830-25-000027|0) | 237 ["Taxes paid"](0001306830-25-000027|0) | 273 ["Taxes paid"](0001306830-25-000027|0) | Management explains the FY2024 OCF decline (vs. FY2023) primarily via **unfavorable trade working capital**, **lower earnings excluding non-cash impairment effects**, and **higher cash taxes**. ["unfavorable trade working capital"](0001306830-25-000027|0) ["decrease in Net earnings"](0001306830-25-000027|0) ["increase in cash taxes paid"](0001306830-25-000027|0) --- ## 4) Segment economics: where the money is made (and lost) ### Table C — Segment P&L (reportable segments + “Other Activities”) (USD millions) | Year | Segment | Net sales | Operating profit (loss) | Notable driver inside segment view | |---|---|---:|---:|---| | FY2024 | Engineered Materials | 5,607 ["Net sales 5,607"](0001306830-25-000027|0) | (1,179) ["Operating profit (loss) (1,179)"](0001306830-25-000027|0) | Other charges (incl. impairment) concentrated here ["Other (charges) gains, net"](0001306830-25-000027|0) | | FY2024 | Acetyl Chain | 4,763 ["Net sales 4,763"](0001306830-25-000027|0) | 951 ["Operating profit (loss) 951"](0001306830-25-000027|0) | More resilient operating profit than EM in FY2024 ["Operating profit (loss) 951"](0001306830-25-000027|0) | | FY2024 | Other Activities | — ["—"](0001306830-25-000027|0) | (469) ["(469)"](0001306830-25-000027|0) | Corporate/other costs live here ["Other Activities"](0001306830-25-000027|0) | | FY2023 | Engineered Materials | 6,149 ["Net sales 6,149"](0001306830-25-000027|0) | 1,083 ["Operating profit (loss) 1,083"](0001306830-25-000027|0) | FY2023 includes JV gain & much lower charges ["Gain (loss) on disposition"](0001306830-25-000027|0) | | FY2023 | Acetyl Chain | 4,884 ["Net sales 4,884"](0001306830-25-000027|0) | 1,109 ["Operating profit (loss) 1,109"](0001306830-25-000027|0) | — | | FY2022 | Engineered Materials | 4,024 ["Net sales 4,024"](0001306830-25-000027|0) | 429 ["Operating profit (loss) 429"](0001306830-25-000027|0) | — | | FY2022 | Acetyl Chain | 5,743 ["Net sales 5,743"](0001306830-25-000027|0) | 1,447 ["Operating profit (loss) 1,447"](0001306830-25-000027|0) | — | **Interpretation (what this implies structurally):** - Celanese’s consolidated volatility in FY2024 is **not** “broad-based margin collapse” alone—it is **heavily driven by Engineered Materials** swinging from profit to a large operating loss, while Acetyl Chain remained solidly profitable. ["Operating profit (loss)"](0001306830-25-000027|0) --- ## 5) Balance sheet & leverage: the central strategic constraint ### 5.1 Balance sheet snapshot (FY2024 year-end, GAAP) From the FY2024 10-K consolidated balance sheet: - **Total assets:** $22,857 million. ["Total assets 22,857"](0001306830-25-000027|0) - **Goodwill:** $5,387 million; **Intangibles, net:** $3,641 million. ["Goodwill 5,387"](0001306830-25-000027|0) ["Intangible assets, net 3,641"](0001306830-25-000027|0) - **Long-term debt (net):** $11,078 million; **Total debt:** $12,579 million; **Cash:** $962 million. ["Long-term debt"](0001306830-25-000027|0) ["Total debt"](0001306830-25-000027|0) ["Cash and cash equivalents 962"](0001306830-25-000027|0) ### 5.2 Debt stack (FY2024 year-end): “many notes + term loan + revolver” The 10-K gives a detailed long-term debt schedule (USD millions). Here’s the “shape” of it: - Senior notes across multiple maturities (2025 through 2033), plus a **term loan due 2027 ($880m)**, plus bonds/loans/finance leases. ["Senior unsecured term loan due 2027"](0001306830-25-000027|0) - The 10-K notes that an **S&P downgrade to BB+** increased coupon rates (step-ups) for certain notes. ["downgraded… to BB+"](0001306830-25-000027|0) ### Table D — Selected long-term debt lines at Dec 31, 2024 (USD millions) | Instrument (selected) | Balance | |---|---:| | Senior unsecured term loan due 2027 | 880 ["term loan due 2027"](0001306830-25-000027|0) | | Senior unsecured notes due 2027, 6.165% | 2,000 ["notes due 2027"](0001306830-25-000027|0) | | Senior unsecured notes due 2032, 6.379% | 1,000 ["notes due 2032"](0001306830-25-000027|0) | | Senior unsecured notes due 2033, 6.700% (step-up noted) | 1,000 ["notes due 2033"](0001306830-25-000027|0) ["increasing the interest rates"](0001306830-25-000027|0) | | Total long-term debt (gross subtotal) | 12,527 ["Subtotal 12,527"](0001306830-25-000027|0) | | Less: current installments | (1,393) ["Current installments"](0001306830-25-000027|0) | | Long-term debt (net) | 11,078 ["Total 11,078"](0001306830-25-000027|0) | ### 5.3 “Deleveraging mode” becomes explicit in 2025 disclosures In the Q3 2025 10-Q, management explicitly discusses leverage and steps taken: - They state the M&M Acquisition increased leverage and they **paused share repurchases**, and **reduced the quarterly dividend by ~95% beginning in Q1 2025** (as part of deleveraging). ["paused our share repurchase program"](0001306830-25-000225|0) ["reduce our quarterly dividend by approximately 95 percent"](0001306830-25-000225|0) - They also describe refinancing/tender activity and a new revolving credit agreement. ["new revolving credit agreement"](0001306830-25-000225|0) --- ## 6) “Watch items” that dominate the debate: impairments + restructuring + cyclicality ### 6.1 Impairments (repeat theme across 2024–2025) - FY2024: Celanese shows **impairment losses impacting goodwill** (Engineered Materials) in the goodwill rollforward. ["Impairment losses (1,517)"](0001306830-25-000027|0) - Q3 2025: Celanese reports a **non-cash goodwill impairment loss of $1.1 billion** and **trade name impairments (including Zytel®)**; it also notes an annual indefinite-lived intangible impairment loss of **$346 million** (primarily Zytel®). ["impairment loss on goodwill of $1.1 billion"](0001306830-25-000225|0) ["impairment loss of $346 million"](0001306830-25-000225|0) **Why this matters:** when goodwill/intangibles are a large fraction of assets (FY2024: goodwill $5.387B + intangibles $3.641B), the equity story becomes sensitive to (i) discount rates and (ii) end-market assumptions used in impairment testing. ["Goodwill 5,387"](0001306830-25-000027|0) ["Intangible assets, net 3,641"](0001306830-25-000027|0) ### 6.2 Restructuring and footprint actions FY2024 includes plant closure actions (e.g., Uentrop Germany polymerization units and Mechelen Belgium facility) with exit/shutdown costs disclosed in Note 4. ["intended closure"](0001306830-25-000027|0) ["Total 90"](0001306830-25-000027|0) ### 6.3 Cyclicality & end-market demand In Q3 2025 MD&A, Celanese attributes Net sales declines to **lower volumes (weaker global economic conditions)** and **pricing pressure** (especially Acetyl Chain supply/demand imbalance). ["weaker global economic conditions"](0001306830-25-000225|0) ["greater supply than demand"](0001306830-25-000225|0) --- ## 7) Governance & incentives (proxy disclosures) ### 7.1 Board refreshment + leadership structure The 2025 proxy describes board refreshment since 2022 and a transition to an **independent Chair** structure in 2025 (and dissolution of the Lead Independent Director role as of Dec 31, 2024). ["moving from… Lead Independent Director… to an Independent Chair"](0001306830-25-000083|0) ["role of Lead Independent Director was dissolved"](0001306830-25-000083|0) ### 7.2 How the proxy frames performance (useful “management lens”) The proxy’s performance highlight section states FY2024: - **Net sales $10,280m**, **GAAP diluted loss per share of $13.86**, and **Adjusted EPS of $8.37** (non-GAAP). ["2024 net sales of $10,280"](0001306830-25-000083|0) ["GAAP diluted loss per share of $13.86"](0001306830-25-000083|0) ["Adjusted EPS(1) of $8.37"](0001306830-25-000083|0) *(Those non-GAAP measures are in the proxy with reconciliations referenced to Exhibit A, but the detailed recon is not included in the excerpt we pulled.)* ["See “Exhibit A”"](0001306830-25-000083|0) ### 7.3 Director compensation structure (baseline economics of governance) The proxy spells out the base director comp components and committee chair fees. ["Annual cash retainer"](0001306830-25-000083|0) ["Annual time-based restricted stock units"](0001306830-25-000083|0) --- ## 8) A practical “investor checklist” (built from the disclosures above) ### A) Earnings quality / normalization - Separate **core operating performance** from **Other (charges) gains** (FY2024 included $(1.744)B). ["Other (charges) gains, net"](0001306830-25-000027|0) - Track whether impairment risk continues (Q3 2025 shows additional large impairments). ["Asset impairments"](0001306830-25-000225|0) ### B) Deleveraging trajectory - Monitor **total debt vs. cash** and debt maturity/refinancing actions. ["Total debt"](0001306830-25-000027|0) ["Cash and cash equivalents"](0001306830-25-000027|0) - Watch capital allocation: they explicitly **paused repurchases** and **cut dividends ~95%** starting Q1 2025. ["paused our share repurchase program"](0001306830-25-000225|0) ["reduce our quarterly dividend by approximately 95 percent"](0001306830-25-000225|0) ### C) Segment inflection signals - Engineered Materials: volume/pricing + any incremental “other charges.” ["Operating profit (loss)"](0001306830-25-000027|0) - Acetyl Chain: spread environment (supply > demand) + lag effects. ["greater supply than demand"](0001306830-25-000225|0) ### D) ESG / climate disclosure risk (not “ESG marketing”—financial/regulatory angle) Celanese explicitly flags climate-related **regulatory, physical, and transition risks** in its risk-factor discussion and notes ongoing GHG measurement/reporting efforts. ["financial, regulatory, physical and transition risks"](0001306830-25-000027|0) ["Scope 1 and Scope 2"](0001306830-25-000027|0) --- If you want to “use this interactively” without any back-and-forth: treat Sections **2–6** as modules. The fastest way to go deeper is to anchor on **(i) Engineered Materials impairment + recovery**, **(ii) Acetyl Chain cycle**, or **(iii) refinancing/deleveraging path**, because those are the main drivers repeatedly emphasized across the 10-K and 10-Q. ["Other (charges) gains, net"](0001306830-25-000027|0) ["greater supply than demand"](0001306830-25-000225|0) ["deleveraging efforts"](0001306830-25-000225|0)